Journal Article Review Research Support, Non-U.S. Gov't Epublish 3 citations
PubMed: 38915099 DOI: 10.1186/s13045-024-01568-z
Advances in CAR-T-cell therapy in T-cell malignancies.
J Hematol Oncol 17(1):49
Authors: Rubing Zheng, Xiaojian Zhu, Yi Xiao
Affiliations
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Abstract
Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of aggressive T-cell malignancies. This article reviews the challenges of CAR-T-cell therapy in treating T-cell malignancies and summarizes the progress of preclinical and clinical studies in this area. We present an analysis of clinical trials of CAR-T-cell therapies for the treatment of T-cell malignancies grouped by target antigen classification. Moreover, this review focuses on the major challenges encountered by CAR-T-cell therapies, including the nonspecific killing due to T-cell target antigen sharing and contamination with cell products during preparation. This review discusses strategies to overcome these challenges, presenting novel therapeutic approaches that could enhance the efficacy and applicability of CAR-T-cell therapy in the treatment of T-cell malignancies. These ideas and strategies provide important information for future studies to promote the further development and application of CAR-T-cell therapy in this field.
MeSH
Cells, Hematology, Therapeutics, T-Lymphocytes, Car-T Cell
Cited by
- Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer. Front Immunol, 2025
- Emerging Multifunctional Biomaterials for Addressing Drug Resistance in Cancer. Biology (Basel), 2025
- CD7 CAR-T therapy: current developments, improvements, and dilemmas. Blood Sci, 2025
- Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges. Viruses, 2025
- CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights. Front Immunol, 2025
- T cells in cancer: mechanistic insights and therapeutic advances. Biomark Res, 2025
- Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. J Hematol Oncol, 2024